HC Wainwright Analysts Increase Earnings Estimates for ZVRA

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Zevra Therapeutics to $0.55 from $0.23, slightly above the current consensus estimate of $0.52.
• Zevra beat earnings and revenue expectations in its latest quarterly report, posting $0.18 EPS versus the $0.06 consensus and revenue of $36.22 million versus $31.96 million expected.
• Analyst sentiment remains positive overall, with eight Buy ratings and one Hold rating, and an average target price of $23.33 on the stock.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at HC Wainwright boosted their FY2026 earnings per share estimates for Zevra Therapeutics in a research report issued on Thursday, May 7th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.55 per share for the year, up from their previous forecast of $0.23. The consensus estimate for Zevra Therapeutics' current full-year earnings is $0.52 per share.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%.The business had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million.

Several other equities research analysts have also recently issued reports on the company. BTIG Research assumed coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a "buy" rating and a $23.00 target price on the stock. Wall Street Zen raised Zevra Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, April 11th. Guggenheim lifted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Friday. Finally, Weiss Ratings raised Zevra Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $23.33.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock opened at $11.13 on Monday. The stock's 50-day simple moving average is $9.73 and its 200-day simple moving average is $9.25. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $13.16. The company has a market capitalization of $658.01 million, a price-to-earnings ratio of 5.59 and a beta of 0.88.

Institutional Investors Weigh In On Zevra Therapeutics

Several large investors have recently made changes to their positions in ZVRA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares during the last quarter. Strs Ohio bought a new stake in Zevra Therapeutics during the first quarter worth approximately $125,000. Creative Planning bought a new stake in Zevra Therapeutics during the second quarter worth approximately $92,000. Rhumbline Advisers increased its stake in Zevra Therapeutics by 11.6% during the second quarter. Rhumbline Advisers now owns 83,221 shares of the company's stock worth $733,000 after acquiring an additional 8,636 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Zevra Therapeutics during the second quarter worth approximately $255,000. 35.03% of the stock is owned by institutional investors.

Key Stories Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: HC Wainwright raised Zevra’s Q2 2026 EPS estimate to $0.06 from $0.03, signaling better near-term earnings expectations.
• Positive Sentiment: The firm also increased Q3 2026 EPS estimates to $0.11 from $0.08 and Q4 2026 EPS estimates to $0.17 from $0.12, reflecting stronger expected profitability.
• Positive Sentiment: HC Wainwright lifted its FY2027 and FY2030 earnings forecasts, suggesting confidence in Zevra’s long-term growth trajectory.
• Neutral Sentiment: One analyst lowered FY2028 and FY2029 estimates slightly, but the changes were modest and did not offset the broader upward revisions. Zevra Therapeutics stock page

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.